• Mashup Score: 0

    September 26, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced today that primary data from the AZALEA-TIMI 71study of patients with atrial fibrillation at moderate-to-high risk of stroke has been selected for a Late Breaking session at the American Heart Association Scientific Sessions 2023, being held November 11-13 in Philadelphia.  This news comes just days after it was announced that the AZALEA-TIMI 71 study was stopped early by the independent Data Monitoring Committee (DMC) due to an overwhelming greater-than-anticipated reduction in major and clinically relevant non-major bleeds in abelacimab compared to rivaroxaban and a benefit/risk profile also favoring abelacimab.  “The substantial reduction in bleeding with the monthly administered, dual-acting Factor XI/XIa inhibitor abelacimab compared to a standard-of-care anticoagulant represents an enormous potential a

    Tweet Tweets with this article
    • @DAICeditor Primary data from the #AZALEA_TIMI_71 study of patients with #atrialfibrillation at moderate-to-high risk of #stroke has been selected for a #LateBreaking session at the #AmericanHeartAssociation Scientific Sessions 2023, being held in Nov.: https://t.co/fYiJPlLw3T

  • Mashup Score: 0

    August 31, 2023 — Atrial fibrillation ablation is associated with lower rates of death, urgent heart transplantation or left ventricular assist device (LVAD) implantation compared with medical therapy in patients with end-stage heart failure, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1  Patients with end-stage heart failure eligible for heart transplantation have been excluded from major trials, leaving them with no recommendations or evidence for the optimal treatment of atrial fibrillation and advanced heart failure. There is uncertainty around the application of guidelines in this group2,3 and many novel advances in heart failure therapy are withheld in clinical practice.  The CASTLE-HTx trial tested whether atrial fibrillation ablation is superior to medical therapy concerning mortality and need for urgent transplantation or LVAD implantation.4 The trial was conducted at the Heart and Diabetes Center North Rhine-Westphalia (NRW)

    Tweet Tweets with this article
    • @DAICeditor @escardio #Atrialfibrillation #ablation is associated with lower rates of death, urgent #hearttransplantation, left ventricular assist device implantation compared with #medicaltherapy in patients with end-stage #heartfailure: https://t.co/BfnDLf6AnS #ESC23 #esc2023

  • Mashup Score: 1

    Some studies of fish oil supplements have shown a higher risk for atrial fibrillation with marine omega-3 fatty acids. Is it real? What are the implications for patients taking these capsules?

    Tweet Tweets with this article
    • Are #FishOils on the Hook for AF Risk? https://t.co/jRUgn48SL7 via @medscape #AtrialFibrillation #CVD #ASCVD Interesting, insightful, and important assessment, but @drjohnm has avoided possible benefits of #fishoil on other aspects of human health, e.g. #NervousSystem. #Brain… https://t.co/h8WriCh8jF

  • Mashup Score: 0

    Levels of omega-3 fatty acids, primarily from diet, were not related to risk for incident atrial fibrillation, according to a meta-analysis published in the Journal of the American College of Cardiology.The findings contrast with results of trials of omega-3 fatty acid supplementation, which found omega-3 fatty acid supplementation was associated with elevated risk for AF.

    Tweet Tweets with this article
    • #ICYMI: Findings published in the Journal of the American College of Cardiology found that #omega3 fatty acid levels, primarily from one's diet, were not related to incident #atrialfibrillation risk. https://t.co/nSTai7Pjlp

  • Mashup Score: 1

    Levels of omega-3 fatty acids, primarily from diet, were not related to risk for incident atrial fibrillation, according to a meta-analysis published in the Journal of the American College of Cardiology.The findings contrast with results of trials of omega-3 fatty acid supplementation, which found omega-3 fatty acid supplementation was associated with elevated risk for AF.

    Tweet Tweets with this article
    • #Omega3 fatty acid levels, primarily from one's diet, were not related to incident #atrialfibrillation risk, according to findings published in the Journal of the American College of Cardiology https://t.co/nSTai7Pjlp